PTC Therapeutics Announces Acquisition of ST-920 Gene Therapy

What Happened
On August 12, 2026, PTC Therapeutics, Inc. announced it was the winning bidder to acquire ST-920, a BLA‑stage, one‑time AAV gene therapy candidate for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The planned deal calls for a $111 million upfront payment and up to $100 million in contingent milestone payments ($80M on accelerated approval and $20M on traditional/full FDA approval). The transaction is subject to final documentation, bankruptcy court approval, antitrust review and other customary closing conditions; closing is expected late Q3 or early Q4 2026.

Key Details

• Acquisition announced: August 12, 2026; filing made on Form 8‑K (Regulation FD disclosure and Other Events).
• Cash consideration: $111 million upfront plus up to $100 million contingent ($80M for accelerated approval; $20M for full approval).
• Regulatory plan & timing: rolling BLA submission to FDA for accelerated approval expected to be completed in Q4 2026; BLA based on 52‑week Phase 1/2 STAAR data showing favorable renal effect and safety/tolerability.
• Conditions: Transaction requires final agreements, bankruptcy court approval, antitrust clearance, and other customary closing conditions.

Why It Matters
This acquisition, if completed, adds a late‑stage gene therapy candidate (ST‑920) targeting Fabry disease to PTC’s pipeline with a defined near‑term regulatory path (rolling BLA toward accelerated approval). The structured payments ($111M upfront, contingent milestones) clarify near‑term cash commitments and potential future earnouts tied to FDA milestones. Because the deal hinges on bankruptcy court approval and other conditions, investors should note the acquisition is not final and outcomes (timing, approval, commercialization) remain uncertain per the company’s forward‑looking disclosures.